Auro Laboratories share news, announcements and annual reports
BSE: 530233Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 30 Oct 2026. Previous close ₹232.75.
30 Oct: open ₹234.00, high ₹234.00, low ₹225.00
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹145 Cr2,545th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 30.97
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.13
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 8.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 1.37
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 648
Auro Laboratories share news and announcements
442 announcements, routine notices left out, newest first. Page 4 of 9.
Jul 2022
5 Jul · Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Jun 2022
May 2022
31 May · Disclosure Of Related Party Transactions For The Half Year Ended March 31, 2022
31 May · Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
31 May · Disclosure Under Regulation 30(5) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
20 May · Board meeting
Meeting on 30 May 2022: audited results and quarterly results
Apr 2022
15 Apr · Certificates Under Regulation 40(9) Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
8 Apr · Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended March 31, 2022
4 Apr · Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Jan 2022
19 Jan · Shareholding for the Period Ended December 31, 2021
Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click ....19 Jan · Board meeting
Meeting on 28 Jan 2022: quarterly results11 Jan · Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 1 1 011 Jan · Legal
Exchange has sought clarification from Auro Laboratories Ltd on January 11, 2022 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Dec 2021
Nov 2021
Oct 2021
29 Oct · Board meeting
Meeting on 11 Nov 2021: quarterly results20 Oct · Shareholding for the Period Ended September 30, 2021
Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click ....8 Oct · Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 2 2 0
Sep 2021
1 Sep · Results
Details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly ....
Aug 2021
5 Aug · Results
Jul 2021
26 Jul · Board meeting
Meeting on 5 Aug 2021: quarterly results17 Jul · Shareholding for the Period Ended June 30, 2021
Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click ....